US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Inhalation Sciences signs CRO contract worth 900,000 SEK with Akari Therapeutics

(Stockholm 17 November 2021) Inhalation Research Services, ISAB’s contract research organization, has signed a contract with Akari Therapeutics, a UK pharma company developing a novel biologic molecule, Nomacopan, to treat orphan inflammatory diseases in difficult-to-treat areas, including pulmonary conditions. The contract is for a comprehensive pharmacokinetic study using ISAB’s high-precision Isolated Perfused Lung (IPL) method.Akari Therapeutics’ lead compound, nomacopan is a novel biologic therapy that inibits both the complement (C5) and leukotriene (LTB4) pathways. It is currently in

Inhalation Sciences signs exclusive distribution agreement with Apex Inhalation for sales expansion into India, Bangladesh and Sri Lanka

(Stockholm, Sweden, April 22, 2021) ISAB has signed an exclusive distribution agreement with Apex Inhalation, a spinoff of Apex Chromatography, one of South Asia’s leading suppliers of laboratory equipment. The region is one of the world’s largest and fastest-growing inhalation R&D markets with many global pharma companies having large-scale research and manufacturing facilities there. The agreement covers India, Bangladesh and Sri Lanka, and the potential in sales of instruments and services is estimated at over 3 MSEK for the rest of 2021 and 2022.ISAB has signed an agreement with Apex

Inhalation Sciences technology spotlighted by researchers at 4 major industry events

From Austria to Sweden to California to the UK: October has been an intensive month for Inhalation Sciences' flagship aerosol generator PreciseInhale. It has been spotlighted by senior ISAB clients such as Fraunhofer ITEM at four global industry events. “Customers of this calibre sharing the findings they’re achieving really underlines the strategic value we deliver” says ISAB CEO Manoush Masarrat.PreciseInhale has been presented at four different inhalation events in October, each time by clients showcasing specific benefits and findings they got from the system. “The range of events

Inhalation Sciences AB and Clinical Trial Consultants AB collaborate on clinical validation of PreciseInhale

STOCKHOLM, SWEDEN – July 1, 2019. Inhalation Sciences AB (ISAB) has contracted Swedish CRO Clinical Trials Consultants AB to carry out its clinical study validating PreciseInhale for clinical use. CTC CEO Anders Millerhovf: “For us this is a win-win. As an innovation-focussed CRO we appreciate the new value and data that a clinically validated PreciseInhale system will offer the inhalation industry and we look forward to continuing to explore PreciseInhale’s highly competitive capabilities”.ISAB has chosen Swedish CRO CTC to carry out a 15-month study to validate PreciseInhale, its flagship

Precise, controlled aerosols wet or dry: ISAB launches new nebulizer feature

From cystic fibrosis to antibiotics, work on new inhalable biologic therapies is growing. With biologics formulated as liquid solutions, the need for precisely controllable wet, as well as dry, aerosols is crucial. PreciseInhale’s new nebulizer feature meets the need, generating aerosol from liquids—and letting researchers choose to  deliver them as either wet or dry aerosols to PreciseInhale’s wide range of exposure modules.“Wet or dry aerosol isn’t really the question,” says ISAB CSO Per Gerde. “Precise aerosols and results—or not. That’s what’s really important for drug developers.”

Ziccum AB (publ) share issue oversubscribed before listing on Spotlight

STOCKHOLM, SWEDEN 9 October. On October 3, 2018, the subscription period for Ziccum's new issue of units was completed, prior to its planned listing on Spotlight. The new issue of 15.8 MSEK was subscribed to approximately 52.7 MSEK including subscription commitments, a subscription ratio of approximately 334%. Ziccum will therefore receive a total of 15.8 MSEK before issue costs of approx. 1 MSEK, while increasing the number of shareholders to approximately 1000. Settlement notes for units subscribed without preference under the new terms and conditions was issued on October 8, 2018.CEO

Inhalation Sciences’ subsidiary Ziccum announces approval for listing on Spotlight.

STOCKHOLM, SWEDEN – 14 September, 2018. Inhalation Sciences subsidiary Ziccum has been approved for listing on Stockholm stock market Spotlight, provided that the minimum limit of the company's new issue and the marketplace's proprietary spread requirements are met. The subscription period for the company's new share issue will begin on September 19 and continue until October 3, 2018. The first day of trading on Spotlight is scheduled for October 25, 2018.The new issue will take place with preference for Inhalation Sciences’ shareholders. Shareholders in Ziccum receive a unit right for each

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe